Latest innovations feature vendor-neutral solutions to help reduce clinical complexity and enhance operational efficiency
Steve joins Sai Life Sciences from GlaxoSmithKline (GSK) where he was a department head and member of the global chemical development leadership team.
She will provide strategic advice and scientific leadership to support clients in clinical development, registration strategy, submission, early post-approval strategy
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
Acquisition expands Merck’s growing hematology portfolio
The newly built complex of RRIUM, which will be under CCRUM, the apex government organization for research in Unani Medicine
Omicron BA.5 continues to be the most prevalent sublineage in the United States (nearly 30% of cases) at the time of publication of the data
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Nikon’s newly launched product AXR Point scanning confocal microscope provides “World’s largest Field of View” of 25mm in one single shot
Subscribe To Our Newsletter & Stay Updated
